Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Bionomics Limited

    NASDAQ: BNOX · Real-Time Price · USD
    0.25
    0.01 (3.31%)
    At close: Dec 23, 2024, 9:00 PM
    3.31%
    Bid n/a
    Market Cap 4.95M
    Revenue (ttm) 761.65K
    Net Income (ttm) -18.2M
    EPS (ttm) -14.32
    PE Ratio (ttm) -0.017674581005586592
    Forward PE n/a
    Analyst Buy
    Ask n/a
    Volume 906,395
    Avg. Volume (20D) 881,890
    Open 0.25
    Previous Close 0.24
    Day's Range 0.24 - 0.29
    52-Week Range 0.24 - 16.32
    Beta -0.07

    About BNOX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol BNOX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for BNOX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    6 months ago
    Bionomics shares are trading higher after the comp... Unlock content with Pro Subscription
    7 months ago
    Bionomics shares are trading lower. The company shareholders will vote on re-domiciling to the US.
    news image

    1 year ago · investorplace.com

    7 Strong Buy Stocks Under $20: February 2024

    Small-cap stocks are particularly vulnerable to higher interest rates. So it's not surprising that many of these stocks are struggling in a higher-for-longer rate environment.

    news image

    1 year ago · pennystocks.com

    Penny Stocks To Buy? 3 That Insiders Are Investing $100,000+ In Now

    When constructing a watch list of penny stocks, it is wise to closely monitor any legal insider trading activity. Though the rules surrounding insider trades are complex, legal filings by company exec...

    news image

    1 year ago · zacks.com

    Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%

    Bionomics (BNOX) announces positive top-line results from its mid-stage study of BNC210 for the treatment of Post-Traumatic Stress Disorder. The stock of the company rallies 244%.

    news image

    1 year ago · proactiveinvestors.com

    Bionomics shares soar almost 400% after positive phase IIb results from PTSD treatment

    Shares of Bionomics Limited rocketed 387% after phase IIb trial results showed its lead asset had the potential to become a best-in-class treatment for post-traumatic stress disorder (PTSD). Researche...

    news image

    1 year ago · investorplace.com

    Why Is Bionomics (BNOX) Stock Up 347% Today?

    Bionomics (NASDAQ: BNOX ) stock is rocketing higher on Thursday alongside results from a clinical trial. The clinical-stage biotechnology company revealed results from its Phase 2b ATTUNE trial of BNC...

    news image

    1 year ago · marketwatch.com

    Bionomics announces positive results in trial of treatment for PTSD

    The stock of microcap Bionomics Ltd. rose 36% early Thursday, after the company reported positive results from a mid-stage trial of a treatment for post-traumatic stress disorder.

    news image

    1 year ago · zacks.com

    Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate

    Bionomics (BNOX) gains as it provides updates on further development of its lead pipeline candidate, BNC210, developed for post-traumatic stress disorder and social anxiety disorder.

    Add to Watchlist